`U.S. Patent No. 6,331,415
`Filed on behalf of: Sanofi Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________
`
`SANOFI-AVENTIS U.S. LLC AND
`REGENERON PHARMACEUTICALS, INC.,
`Petitioners
`
`v.
`
`GENENTECH, INC. AND CITY OF HOPE,
`Patent Owners
`____________________________________
`
`Case IPR2015-01624
`Patent 6,331,415
`
`____________________________________
`
`PETITIONERS’ CURRENT EXHIBIT LIST
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`PETITIONERS’ CURRENT EXHIBIT LIST
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioners Sanofi Aventis U.S. LLC
`
`(“Sanofi”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) (collectively,
`
`“Petitioners”) hereby submit a current list of exhibits.
`
`Exhibit
`No.
`
`Description
`
`1001
`
`1002
`
`1003
`
`1004
`
`1005
`
`1006
`
`1007
`
`1008
`
`1009
`
`1010
`
`1011
`
`1012
`
`1013
`
`U.S. Patent No. 6,331,415
`
`U.S. Patent No. 4,495,280
`
`Riggs and Itakura, Synthetic DNA and Medicine, American Journal
`of Human Genetics, 31:531-538 (1979)
`Southern and Berg, Transformation of Mammalian Cells to
`Antibiotic Resistance with a Bacterial Gene Under Control of the
`SV40 Early Region Promoter, Journal of Molecular and Applied
`Genetics, 1:327-341 (1982)
`U.S. Patent No. 4,237,224
`
`Declaration of Jefferson Foote, Ph.D., in Support of Sanofi And
`Regeneron's Petition for Inter Partes Review of U.S. Patent No.
`6,331,415
`
`U.S. Patent No. 4,816,657
`
`'415 patent reexamination, Office Action dated 2/16/07
`
`'415 patent reexamination, Owners' Resp. dated 11/25/05
`
`'415 patent reexamination, Owners' Resp. (5/21/07)
`
`'415 patent reexamination, Office Action dated 9/13/05
`
`U.S. Patent No. 4,816,397
`
`'415 patent file history, paper no. 17
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`Exhibit
`No.
`
`Description
`
`1014
`
`1015
`
`1016
`
`1017
`
`1018
`
`1019
`
`1020
`
`1021
`
`1022
`
`1023
`
`1024
`
`1025
`
`1026
`
`1027
`
`1028
`
`1029
`
`'415 patent file history, paper no. 14
`
`'415 patent file history, paper no. 18
`
`'415 patent reexamination, Office Action dated 8/16/06
`
`'415 patent reexamination, Office Action dated 2/25/08
`
`U.S. Patent No. 4,399,216
`
`U.S. Patent No. 5,840,545
`
`Rice and Baltimore, Regulated Expression of an Immunoglobulin K
`Gene Introduced into a Mouse Lymphoid Cell Line, Proceedings of
`the National Academy of Sciences USA, 79:7862-7865 (1982)
`
`Ochi et al., Transfer of a Cloned Immunoglobulin Light-Chain Gene
`to Mutant Hybridoma Cells Restores Specific Antibody Production,
`Nature, 302:340-342 (1983)
`
`'415 patent reexamination, Owners' Resp. dated 10/30/06
`
`'415 patent reexamination, Owners' Resp. dated 6/6/08
`
`'415 patent reexamination, Appeal Brief
`
`'415 patent reexamination, Notice of Intent to Issue Ex Parte
`Reexamination Certificate
`
`'415 reexamination, Ex Parte Reexamination Certificate
`
`T.J.R. Harris, Expression of Eukaryotic Genes in E. Coli, in Genetic
`Engineering 4, 127-185 (1983)
`
`'415 patent reexamination, Declaration of Dr. Timothy John Roy
`Harris under 37 C.F.R. § 1.132
`
`Kabat et al., Sequences of Proteins of Immunological Interest (1983)
`(excerpt)
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`Exhibit
`No.
`
`Description
`
`1030
`
`1031
`
`1032
`
`1033
`
`1034
`
`1035
`
`1036
`
`1037
`
`1038
`
`1039
`
`1040
`
`1041
`
`1042
`
`1043
`
`Cohen, Recombinant DNA: Fact and Fiction, Science, 195:654-657
`(1977)
`
`Oi et al., Immunoglobulin Gene Expression in Transformed
`Lymphoid Cells, Proceedings of the National Academy of Sciences
`USA, 80:825-829 (1983)
`
`European Patent Application Publication No. 0044722 A1, published
`1/27/82
`
`U.S. Patent No. 4,487,835
`
`U.S. Patent No. 4,371,614
`
`U.S. Patent No. 4,762,785
`
`U.S. Patent No. 4,476,227
`
`U.S. Patent No. 4,362,867
`
`U.S. Patent No. 4,396,601
`
`Milstein, Monoclonal Antibodies from Hybrid Myelomas,
`Proceedings of the Royal Society of London, 211:393-412 (1981)
`
`Ochi et al., Functional Immunoglobulin M Production after
`Transfection of Cloned Immunoglobulin Heavy and Light Chain
`Genes into Lymphoid Cells, Proceedings of the National Academy of
`Sciences USA, 80:6351-6355 (1983)
`
`MedImmune, Inc. v. Genentech, Inc., No. 03-02567 (C.D. Cal. Aug.
`17, 2007), Expert Report of E. Fintan Walton
`
`'415 patent reexamination, Request for Reconsideration and/or
`Petition Under 37 C.F.R. § 1.183 dated 5/15/09
`
`Feldman et al., Lessons from the Commercialization of the Cohen-
`Boyer Patents: The Stanford University Licensing Program, in
`Intellectual Property Management in Health and Agricultural
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`Exhibit
`No.
`
`Description
`
`Innovation: A Handbook of Best Practices, 1797-1807 (2007)
`ReoPro® Prescribing Information
`
`Genentech v. Centocor, No. 94-01379 (N.D. Cal.), Affidavit of John
`Ghrayeb, Ph.D.
`
`'415 patent reexamination, Declaration of Dr. E. Fintan Walton under
`37 C.F.R. § 1.132
`
`Complaint in MedImmune v. Genentech, No. 03-02567 (C.D. Cal.)
`
`Stipulation and order of dismissal in MedImmune v. Genentech, No.
`03-02567 (C.D. Cal.)
`
`Complaint in Centocor v. Genentech, No. 08-CV-3573 (C.D. Cal.)
`
`Order of dismissal in Centocor v. Genentech, No. 08-CV-3573 (C.D.
`Cal.)
`
`Complaint in Glaxo Group Ltd. v. Genentech, No. 10-02764 (C.D.
`Cal.)
`
`Order of dismissal in Glaxo Group Ltd. v. Genentech, No. 10-02764
`(C.D. Cal.)
`
`Complaint in Human Genome Sciences v. Genentech, No. 11-CV-
`6519 (C.D. Cal.)
`
`Order of dismissal in Human Genome Sciences v. Genentech, No.
`11-CV-6519 (C.D. Cal.)
`
`Complaint in Eli Lilly and ImClone Systems LLC v. Genentech, No.
`13-CV-7248 (C.D. Cal.)
`
`Stipulation of dismissal in Eli Lilly and ImClone Systems LLC v.
`Genentech, No. 13-CV-7248 (C.D. Cal.)
`
`Complaint in Bristol-Myers Squibb v. Genentech, No. 13-CV-5400
`(C.D. Cal.)
`
`1044
`
`1045
`
`1046
`
`1047
`
`1048
`
`1049
`
`1050
`
`1051
`
`1052
`
`1053
`
`1054
`
`1055
`
`1056
`
`1057
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`Exhibit
`No.
`
`Description
`
`1058
`
`1059
`
`Stipulation of dismissal in Bristol-Myers Squibb v. Genentech, No.
`13-CV-5400 (C.D. Cal.)
`
`Declaration of Lisa M. Ferri in Support of Motion to Appear Pro
`Hac Vice on Behalf of Petitioners Sanofi-Aventis U.S. LLC and
`Regeneron Pharmaceuticals
`
`1060
`
`Professional Profile of Lisa M. Ferri
`
`Dated: August 31, 2015
`
`Respectfully submitted,
`
`By:
`Richard McCormick (Reg. No. 55,902)
`Lisa M. Ferri (pro hac vice)
`Brian W. Nolan (Reg. No. 45,821)
`MAYER BROWN LLP
`1221 Avenue of the Americas
`New York, NY 10020-1001
`Attorneys for Petitioners sanofi-aventis U.S.
`LLC and Regeneron Pharmaceuticals, Inc.
`
`
`
`Case IPR2015-01624
`U.S. Patent No. 6,331,415
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that true and correct copies of the foregoing Petitioners’
`Current Exhibit List was served on August 31, 2015, via UPS OVERNIGHT
`service to counsel for Patent Owners at the following address:
`
`Adam R. Brausa (Reg. No. 60,287)
`Daralyn Durie (pro hac pending)
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`Dated: August 31, 2015
`
`Respectfully submitted,
`
`/Richard J. McCormick/
`Richard J. McCormick, (No. 55,902)
`rmccormick@mayerbrown.com
`MAYER BROWN LLP
`1221 Avenue of the Americas
`New York, NY 10020-1001
`Telephone: (212) 506-2382
`Fax: (212) 849 5682